Evofem Biosciences, Inc. (EVFM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 8 | 17 | 18 | 19 | 20 | 18 | - |
| Operating profit | $m | 1 | -5 | ||||||
| Net profit | $m | -142 | -205 | -77 | 53 | -9 | 0 | - | - |
| EPS reported | $ | 0.00 | -0.05 | ||||||
| Operating cashflow per share | $ | -0.02 | -0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.02 | -0.00 | ||||||
| Free cash flow | $m | -2 | -0 | ||||||
| Net debt | $m | 54 | 68 | ||||||
| Book value equity | $m | -69 | -82 | ||||||
| Book value per share | $ | -0.01 | -0.60 | ||||||
| Number of shares | m | 6,421.75 | 137.34 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.02 | -0.01 | ||||||
| P/S LTM | x | 0.06 | 0.07 | ||||||
| P/FCF LTM | x | -0.59 | -2.46 | ||||||
| EV/EBITDA LTM | x | 26.70 | -12.91 | ||||||
| EV/Sales LTM | x | 2.73 | 2.52 | ||||||
| Earnings Yield LTM | % | +33.28% | -6.22% | ||||||
| FCF Yield | % | -169.99% | -40.60% | ||||||
| Quality | |||||||||
| ROE | % | -0.56% | +8.58% | ||||||
| ROIC | % | -14.24% | +18.31% | ||||||
| Operating margin | % | +7.13% | -17.08% | ||||||
| Gross margin | % | +74.65% | +74.13% | ||||||
| FCF/Sales | % | -9.89% | -1.27% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +4.23% | -6.81% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +9.96% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | -0.12% | ||||||
| FCF/Debt | x | -0.04 | -0.01 | ||||||
| Net Debt/EBITDA | x | 26.14 | -16.98 | ||||||
| EBIT/Net interest | x | 0.55 | -5.00 | ||||||
| Net debt/market cap | % | +46.28% | +54.07% | ||||||
| Net debt/Equity | x | -0.77 | -0.83 | ||||||
| Gross debt/equity | x | -0.79 | -0.83 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free